Business Wire

Fore Biotherapeutics to Present Phase 1/2a Data on FORE8394, a Next-Generation BRAF Inhibitor, at ESMO 2022

Share

Fore Biotherapeutics, a precision oncology company developing treatments for patients with genetically defined cancers whose current treatment options are limited, today announced that data from the ongoing Phase 1/2a study of lead asset, FORE8394, will be presented in the Developmental Therapeutics poster session at the European Society of Medical Oncology Congress (ESMO) taking place in Paris, France, September 9-13, 2022.

The Phase 1/2a open-label study is assessing FORE8394, a next-generation BRAF inhibitor, in patients with advanced solid and CNS tumors with activating BRAF alterations. The poster presentation will report interim analysis in adults (≥18 years) with V600+ advanced solid & central nervous system tumors, including patients who have not previously received BRAF targeted treatment. FORE8394 is a novel, differentiated BRAF inhibitor that uniquely targets Class 1 (V600) and Class 2 alterations, including fusions, and does not induce paradoxical activation of the RAF/MEK/ERK pathway, a limitation of the current standard of care.

Details for the presentation are as follows:

Title: Efficacy of BRAF Inhibitor FORE8394 in BRAF V600+ Patients
Abstract #: 2098
Presentation #: 466P
Presenter: Eric J. Sherman, Memorial Sloan Kettering Cancer Center
Date: Monday,September 12, 2022
Time: 12:00 -13:00 CEST

About FORE8394
FORE8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF. It was designed to target a wide range of BRAF mutations while sparing wild type forms of RAF. Preclinical studies and clinical trials have shown that its unique mechanism of action effectively inhibits not only the constitutively active BRAFV600 monomers targeted by first-generation RAF inhibitors, but also disrupts constitutively active dimeric BRAF class II mutants, fusions, splice variants and others. Unlike first-generation RAF inhibitors, FORE8394 does not induce paradoxical activation of the RAF/MEK/ERK pathway. As a “paradox breaker,” FORE8394 could therefore treat acquired resistance to current RAF inhibitors, and, more generally, yield improved safety and more durable efficacy than first-generation RAF inhibitors

About Fore Biotherapeutics
Fore Bio is a clinical-stage precision oncology biotechnology company focused on developing treatments for patients with genetically defined cancers whose current treatment options are limited. Lead asset FORE8394 is a Class I/II BRAF inhibitor with demonstrated clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. Leveraging a proprietary functional genomics platform that can screen a wide range of known mutations for cancer-driving genes, the Fore R&D team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options. For more information, please visit www.fore.bio or follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors and Media:
Argot Partners
212.600.1902 | ForeBio@argotpartners.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BGI Preparing to Launch Improved Non-invasive Colorectal Cancer Screening Test, COLOTECT™ 3.029.11.2022 11:54:00 CET | Press release

COLOTECT™ 3.0 is a non-invasive colorectal cancer screening test developed by BGI, and will be launched in early 2023. BGI plans to release pre-clinical case-control data for COLOTECT™ 3.0 at the 2023 ASCO Gastrointestinal Cancers Symposium. The sensitivity for detecting CRC is 96.08%. The sensitivity for detecting advanced precancerous lesions (APL) is 52.5%, which is better than FIT products. COLOTECT™ 3.0 is a non-invasive colorectal cancer (CRC) self-sampling test that can detect the methylation status of exfoliated cell genes and the Fecal Occult Blood in the stool. It can help screen for colorectal cancer and advanced precancerous lesions (APL) even in the absence of active bleeding lesions. Colorectal cancer is the third most common cancer and the second deadly cancer worldwide. There were more than 1.9 million new cases of colorectal cancer in 2020. Older age, a history of bowel disease, a family history of related diseases, having type 2 diabetes, overweight or obesity, certai

Talkdesk Chosen as Wallbox Contact Center Solution29.11.2022 11:30:00 CET | Press release

Talkdesk®, Inc., a global cloud contact center leader for customer-obsessed companies, has been selected by Wallbox as its contact center solution provider. Wallbox selected the Talkdesk solution as part of a digital transformation for their contact center, improving both agent engagement and customer experience (CX). Wallbox is an EV charging and energy management company dedicated to changing the way the world uses energy. The company, headquartered in Barcelona, develops advanced EV charging systems that allow users to better manage their energy use and storage, redefining reliance on the energy grid. With offices worldwide, customers across 113 countries, and a geographically diverse workforce of over 1,000 people, Wallbox is committed to eliminating the barriers to EV adoption and helping to accelerate a global transition to more sustainable, efficient, and smart mobility. Talkdesk CX Cloud™, an end-to-end customer experience solution, will provide Wallbox with a modernized, cloud

Kaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 Drug29.11.2022 11:26:00 CET | Press release

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) will manufacture and supply intermediates to Shionogi & Co., Ltd. (Headquarters: Chuo-ku, Osaka; Chief Executive Officer: Isao Teshirogi, Ph.D.) for use in Xocova®*1 (Ensitrelvir Fumaric Acid) Tablets 125mg, a drug for the treatment of SARS-Cov-2 infection. On November 22, Shionogi received emergency regulatory approval from the Ministry of Health, Labour and Welfare to manufacture and sell Xocova® tablets for treating SARS-Cov-2 infection. Shionogi recognized Kaneka for its long years of experience in manufacturing raw materials for medicines, and selected Kaneka as its main supplier for the drug's intermediates, which require GMP*2 management. The two companies have worked closely together for clinical development, approval application, and establishment of mass production supply chain. Kaneka will continue to improve its manufacturing systems and provide Shionogi with a stable supply of intermediates, play

Truvant Receives Procter & Gamble External Business Partner Excellence Award29.11.2022 10:00:00 CET | Press release

Packaging services provider Truvant is pleased to announce that it has received the Procter & Gamble External Business Partner Excellence Award in recognition of Truvants performance and long-standing relationship with the consumer goods giant. The External Business Partner Excellence Award was created by P&G to honor the contributions of those suppliers that have "gone above and beyond in delivering value" to the business. Truvant is the largest pure-play packaging services provider in the world, delivering manufacturing, packaging, and display solutions to the world’s leading brands. The company delivers high-quality, flexible, efficient, and sustainable packaging solutions that help brands get their products to the consumer in the most efficient way possible. Truvants solutions are designed to reduce costs, improve speed to market, create agility and manage complexity while reducing the impact on the environment. Procter & Gamble is one of the many long-standing clients that have be

Alpega’s Freight Exchange Teleroute Expands Its Ecosystem of Financial Solutions With FastPayment in Poland, Allowing Carriers to Cash out on Their Invoices Withing 2 Hours29.11.2022 10:00:00 CET | Press release

Long payment terms was already one of the most common issues faced in the transportation industry. In Poland specifically, the average time for carriers to receive their money after issuing an invoice, ranges from 45 to 60 days. However, with the unprecedented rising costs of fuel and transport operations, many carriers simply cannot afford to wait that long to receive payment for their delivered transport services. It becomes a threat for the business continuity and a rise in bankruptcies has been witnessed within the carrier community. FastPayment is a solution designed to overcome long payment terms. It is a safe solution and the entire process to request short-term financing for specific invoices is 100% online and without complex formalities, ensuring pay out in a matter of hours. The roll out of FastPayment in Poland is an extension of the service that was already operating successfully in Spain and Benelux. As a true pan-European freight exchange it is crucial to offer an ecosys

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom